XML 346 R19.htm IDEA: XBRL DOCUMENT
v3.26.1

Investments accounted for using the equity method | 12 Months Ended
--- | ---
Dec. 31, 2025
Investments accounted for using the equity method |
Investments accounted for using the equity method | (12) Investments accounted for using the equity method -Accounting Principles- The Group, in the course of its business, may enter into arrangements where it will exercise joint control over entities resulting in classifying these operations as joint ventures or joint operations depending on the rights and obligations arising from the contractual arrangement. Alternatively, it may enter into arrangements where it holds 20 to 50 percent of the voting rights and exercises significant influence resulting in these companies being classified as associate companies. Investments in associates and joint ventures are accounted for using the equity method. The Group’s share of profit of joint ventures is classified within non-operating income (loss) as these operations do not form an integral part of the Group’s financial performance, reflecting its non-core business activities. The Group’s share of profit (loss) of associates is classified below Operating income (loss). Goodwill arising from an acquisition is included in the carrying amount of the investments in joint ventures and associated companies. Equity accounting is discontinued when the carrying amount of the investment together with any long-term interest in a joint venture or in an associate reaches zero, unless the Group has either incurred or guaranteed additional obligations in respect of the joint venture or associate. Impairment of Joint Ventures and Associates The Group tests investments in joint ventures and associates for which it does not possess control, but has significant influence for impairment on a regular basis and when there is objective evidence of impairment as a result of one or more events that occurred after the initial recognition of the net investment. Objective evidence of impairment includes but is not limited to the net asset value being below carrying amount, absence of scientific progress, significant financial difficulties of the joint venture, associate or information about significant changes with an adverse effect that have taken place in the economic environment in which it operates and indicates that the carrying amount may not be recovered. -Investments in associates- Individually immaterial shares in companies accounted for using the equity method are presented in aggregate, provided that at the balance sheet date the equity book value did not exceed € 1,000k or Evotec’s share of earnings in the result (Share of profit in associate and Impairment combined) were less than € 1,000k in the company’s profit or loss. At the balance sheet date, one investment was classified as significant and five investments were classified as insignificant. Further, on December 30, 2025, the Group sold one of its associate investments, Dark Blue Therapeutics Ltd, resulting in a gain on sale and corresponding other operating income of € 12,125k. The additions to the significant investments in 2025 are entirely related to financing rounds (capital contributions). The following table summarizes the development of the investments in associates during year 2025:
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Centauri | ​ | ​ | ​ | ​
​ | ​ | Therapeutics | ​ | Insignificant | ​ | ​
in k€ | ​ ​ ​ | Ltd | ​ ​ ​ | investments | ​ ​ ​ | Total
Balance at January 1, 2025 | ​ | 1,264 | ​ | 874 | ​ | 2,138
Investment | ​ | 3,576 | ​ | — | ​ | 3,576
Share of profit/(loss) in associate | ​ | (634) | ​ | (451) | ​ | (1,085)
Impairment | ​ | — | ​ | — | ​ | —
Dividends earned, Divestment or Reclassification |  | — | ​ | — | ​ | —
Balance at December 31, 2025 |  | 4,206 | ​ | 423 | ​ | 4,629
​ The following table provides an overview of the development of the investments in 2024: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ ​ | ​ | ​ ​ ​ | Centauri | ​ ​ ​ | ​ | ​ | Quantro | ​ | Topas | ​ | ​ | ​ ​ ​ | ​ ​ ​
​ | ​ | Autobahn | ​ | Therapeutics | ​ | EIR | ​ | Therapeutics | ​ | Therapeutics | ​ | Insignificant | ​ | ​
in k€ | ​ ​ ​ | Labs LLC | ​ ​ ​ | Ltd. | ​ ​ ​ | Biotherapies | ​ | GmbH | ​ ​ ​ | GmbH | ​ ​ ​ | investments | ​ ​ ​ | Total
Balance at January 1, 2024 | ​ | — | ​ | 2,179 | ​ | — | ​ | 892 | ​ | — | ​ | — |  | 3,071
Investment | ​ | 1,378 | ​ | — | ​ | 1,022 | ​ | — | ​ | 977 | ​ | 2 | ​ | 3,379
Share of profit/(loss) in associate |  | (1,378) | ​ | (916) | ​ | (149) | ​ | (892) | ​ | (977) | ​ | — | ​ | (4,312)
Impairment |  | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | —
Dividends earned, Divestment or Reclassification | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — |  | —
Balance at December 31, 2024 | ​ | — | ​ | 1,264 | ​ | 873 | ​ | — | ​ | — | ​ | 2 |  | 2,138
​ Further financial information on the significant investments accounted for using the equity method is presented below: ​ 2025 ​
​ | ​ | ​
​ | ​ | Centauri
​ | ​ | Therapeutics
in k€ | ​ ​ ​ | Ltd
Current assets |  | 14,127
Non-current assets |  | 239
Current liabilities |  | 233
Non-current liabilities |  | —
Revenues from Jan 1 to Dec 31 | ​ | 4,837
Net income (loss) Jan 1 to Dec 31 |  | (3,915)
​ 2024 ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ ​ | ​ ​ ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Centauri | ​ | Dark Blue | ​ | ​ | ​ | Quantro | ​ | Topas
​ | ​ | Therapeutics | ​ | Therapeutics | ​ | EIR | ​ | Therapeutics | ​ | Therapeutics
in k€ | ​ ​ ​ | Ltd. | ​ | Ltd. | ​ | Biotherapies | ​ ​ ​ | GmbH | ​ ​ ​ | GmbH
Current assets | ​ | 383 | ​ | 291 | ​ | 634 | ​ | 1,121 | ​ | 7,560
Non-current assets |  | 299 | ​ | 9,047 | ​ | 1,752 |  | 549 |  | 972
Current liabilities |  | 245 | ​ | 981 | ​ | 187 |  | 2,072 |  | 548
Non-current liabilities |  | — | ​ | — | ​ | 2 |  | 4,325 |  | —
Revenues from Jan 1 to Dec 31 | ​ | 1 | ​ | — | ​ | — | ​ | 1,294 | ​ | —
Net income (loss) Jan 1 to Dec 31 |  | (4,483) | ​ | (3,115) | ​ | (167) |  | (3,974) |  | (9,418)
​

X
- Definition The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Note Expiry date 2027-01-01 -Name IAS -Number 1 -IssueDate 2025-01-01 -Paragraph 10 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration